Vertex Pharmaceuticals
VRTX Nasdaq· Biotechnology
Last close · Oct 26, 2026
$517.49
KIRA · Stoqly’s AI analyst, in plain words
- Vertex Pharmaceuticals had $12.0B of revenue in fiscal 2025, up 8.9% on the year before. Over five years, revenue changed +14.1% a year on average.
- Its operating margin was 34.8%, up 36.9 pts: of every 100 in sales, about 35 is left after running the business.
- Vertex Pharmaceuticals made $4.0B of net profit in fiscal 2025.
- Free cash flow was $3.2B in fiscal 2025, 26.6% of revenue.
- Vertex Pharmaceuticals returned $2.0B to shareholders in fiscal 2025, 63% of free cash flow. The diluted share count rose 0.0%.
- Vertex Pharmaceuticals has $6.5B more cash than debt.
Market cap
$132.1B
P/E
30.1x
Revenue
$12.0B
Net income
$4.0B
Free cash flow
$3.2B
Operating margin
34.8%
Vertex Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+8.9%
Yes. Sales grew 8.9% last year.
Does it make a profit?
32.9%
Yes. It keeps 32.9% of every sale as profit.
Does profit turn into cash?
26.6%
Yes. 26.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
30.1x
One share costs 30.1 times its yearly profit per share. Typical for its sector: 27.9x.
What Vertex Pharmaceuticals does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 13, 2026
- Legal name
- VERTEX PHARMACEUTICALS INC / MA
- CIK
- 0000875320
Vertex Pharmaceuticals · VRTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Revenue growth | 22.1% | 17.9% | 10.5% | 11.7% | 8.9% |
| Gross margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating margin | 36.7% | 48.2% | 38.8% | −2.1% | 34.8% |
| Net income | $2.3B | $3.3B | $3.6B | −$536M | $4.0B |
| Net margin | 30.9% | 37.2% | 36.7% | −4.9% | 32.9% |
| Diluted EPS | $9.01 | $12.82 | $13.89 | −$2.08 | $15.32 |
| Cash | |||||
| Cash from operations | $2.6B | $4.1B | $3.5B | −$493M | $3.6B |
| Capital expenditure | $235M | $205M | $200M | $298M | $438M |
| Free cash flow | $2.4B | $3.9B | $3.3B | −$790M | $3.2B |
| FCF margin | 31.8% | 44.0% | 33.8% | −7.2% | 26.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $1.4B | $0.0M | $428M | $1.2B | $2.0B |
| Share count change | −1.3% | −0.3% | 0.5% | −1.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $7.5B | $10.8B | $11.2B | $6.1B | $6.6B |
| Debt incl. finance leases | $557M | $472M | $427M | $118M | $112M |
| Shareholders' equity | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Net debt / EBITDA | −2.4x | −2.3x | −2.7x | — | −1.5x |
| Current ratio | 4.5x | 4.8x | 4.0x | 2.7x | 2.9x |
| Interest coverage | 49.4x | 78.6x | 86.9x | −7.6x | 313.8x |
| Returns and quality | |||||
| Return on capital | 83.1% | 100.4% | 60.9% | −1.4% | 31.5% |
| Return on equity | 24.9% | 27.7% | 23.0% | −3.2% | 22.5% |
| Piotroski F-score | 5 | 7 | 2 | 2 | 6 |
| Altman Z'' | 9.0 | 10.0 | 9.2 | 5.9 | 7.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$158M
13 insiders
Of sales under plans
100%
$158M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vertex Pharmaceuticals · VRTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals VRTX | $132.1B | 8.9% | 34.8% | 26.6% | 31.5% | 30.1x | 6 |
| Regeneron Pharmaceuticals REGN | $85.6B | 1.0% | 25.0% | 28.5% | 12.7% | 20.0x | 5 |
| Biogen BIIB | $37.4B | 2.2% | — | 20.7% | 7.3% | 27.1x | 5 |
| Incyte INCY | $23.4B | 21.2% | 29.5% | 26.4% | 79.4% | 16.0x | 8 |
| Gilead Sciences GILD | $197.3B | 2.4% | 34.0% | 32.1% | 23.0% | — | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $517.49 a share, the company is worth $132.1B: 30.1 times its earnings of the last four quarters.
Vertex Pharmaceuticals grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 3 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000875320). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.